Favorite team:LSU 
Location:Texas
Biography:
Interests:
Occupation:
Number of Posts:11648
Registered on:4/25/2004
Online Status:Not Online

Recent Posts

Message
Yes, I agree with your position on immunity if not your interpretation of the strength of the evidence of glyphosate harms. RFK Jr. stood up for glyphosate's safety, seems to just want to go after Monsanto, says it's the adjuvants not the active ingredients that's harmful. I take it that's not good enough for you? You'd prefer a total ban?
Banning sounds straightforward, but with something this embedded in modern agriculture it would have many knock-on effects (e.g. higher food prices, more soil disturbance, and Big Ag would shift to other chemicals that aren’t obviously better). There's a lot that could be done short of bans with reducing reliance and tightening safeguards rather than flipping a switch overnight, though. Curious if you’d see that as a step in the right direction.
Pointing to specific pathways is good - much more informative than just saying “it’s poison”. The profit angle is also real in agriculture, but it cuts both ways - yield, food prices, farmer economics, and environmental tradeoffs all get mixed in. That’s why people end up arguing about evidence rather than motives. What were you hoping MAHA was going to do with glyphosate?
Yeah - “carcinogenic” by itself doesn’t tell you much. Sunlight, alcohol, and processed meat are all on carcinogen lists too. The meaningful question is always at what dose and exposure? That’s why toxicologists hammered us on the idea that the dose makes the poison - it keeps us from arguing past each other with labels instead of numbers.
Worth separating hazard from risk. glyphosate can cause harm under certain conditions, but that’s true of almost any biologically active chemical. The debate is about risk at real-world exposure levels (this same principle is relevant to the mercury in vaccines vs. emissions issue as well). Some groups classified it as “probably carcinogenic” while some regulators like EPA have generally concluded typical dietary exposure is low risk. That gap is why the issue stays contentious. If we’re going to worry about it, the conversation should probably focus on exposure levels and evidence, not just the fact that it kills plants because things you put in your body all the time without a thought (e.g. salt & caffeine) can also do that.
Good series of posts. Every movement that moves from critique to governing eventually hits this moment - you have to show how you weigh competing risks, not just identify villains. The swings on glyphosate and food dyes is similar to this situation with mercury:

EPA to weaken rule limiting harmful mercury, air toxins from coal plants

If mercury is framed as a major public health concern (e.g., years of debate around thimerosal), then easing mercury limits on coal emissions seems like it would at least require a clear explanation of why that risk is acceptable. What’s the framework here? Cost-benefit? Exposure thresholds? Precautionary principle sometimes but not others?
CCTA has real advantages and incentives absolutely play a role, but I'd complexify this a bit - the situation is probably more layered/messy than a single explanation. Medicine tends to look confusing because it’s trying to optimize several things at once - catching disease early, avoiding cascades of extra testing, managing risk, dealing with insurance constraints, and working within whatever resources a local system actually has. Incentives matter, but large systems usually evolve under a mix of pressures, not one steering wheel.

IOW, beware stories about big systems with only one moving part.
Appreciate that, and I think you’re putting your finger on something important - most people’s views here are shaped by the cases that stick with them, especially when the system feels slow or dismissive. The hard part is that medicine has both incredible successes and very human blind spots, and people tend to encounter one or the other more vividly.

Sounds like we probably agree that the interesting question isn’t whether problems exist, but how to design systems that catch mistakes without making access impossible (which is easier said than done).

These kinds of conversations are rare online, so I’m glad it’s staying thoughtful.
Feels like y'all are actually pointing at the same uncomfortable truth from different angles - that medicine is both incredibly helpful and very fallible. The “docs get it wrong sometimes” stories and the “these drugs are powerful and complicated” concern aren’t really contradictions - they’re two reasons this is a hard policy question.

Part of me says the real question isn’t “trust vs don’t trust”, but where the guardrails should sit given that humans (patients and clinicians) are imperfect and there’s of course a version of this debate that isn’t about who’s naive, but about how much friction we want between people and powerful tools.

The other part of me wants to lean into the trust issue & engage the questions of what would make health professionals and institutions more trustworthy, but maybe that can be blended too, because I think there are some limitations to human improvement and that well-calibrated guardrails in themselves might help the distrust problem, but it's more complex than just that, because our odd information environment sometimes distorts our judgements of trustworthiness.
Sheepish that I missed that. Carry on. :cheers:
He was extending charity to the argument (hence him saying "I doubt it"). I don't blame people for looking for ideas to get health care more cheaply but I agree with you that this one has some significant failure modes (as almost everything does, really). :lol:
Fair point, and I probably should’ve said it more precisely. The proverb isn’t about bandaids or routine self-care. It’s a caution about how even trained people can lose objectivity once they’re both clinician and patient once risk becomes complex (obviously not the case with bandaids).

I agree this is an analog problem. The interesting work is figuring out where along the continuum different drugs belong and not arguing for or against the continuum itself. One way to make the sorting task more concrete is to ask what kind of “friction” each drug needs:

-Labeling alone (true OTC)
-Pharmacist gatekeeping / behind-the-counter
-Time or quantity limits
-Prescriber oversight because of monitoring or stewardship (antibiotics are the obvious example)

Once you start thinking in terms of friction matched to risk rather than a single line the conversation gets a lot more practical.
I've been there. We talk in professional shorthand and forget that words like “superbug” land as sci-fi to a general audience. The interesting part of threads like this is realizing how much translation work there is between “clinical risk” and “how people picture it.” I have to stay humble or get trapped in dominance-display doom loops. :lol:
Actual numbers helps ground the conversation. Resistance seems to act more like an ecosystem signal than a simple policy outcome. OTC access is just one factor - prescribing culture, hospital practices, climate/agriculture, diagnostics, etc. all interact. So Colombia may not “prove” a single cause (in case people are worried that you're cherrypicking), but it does show what can happen when selective pressure accumulates. Makes me wonder which countries have managed broader access without seeing those patterns and what they did differently.
quote:

I'm not sure the policy makers care about the specifics all that much. You can make the argument that even medications like NSAIDs should be more closely monitored given their sundry effects on the body.


Agree, and the dog that hasn't barked in the thread is we're a full five pages in and no one has called this out as a pharma cash grab yet.

Don't make me do your job, baws. :lol:
I’m not sure it’s even a policy yet ( it reads more like a slogan).

“Everything OTC unless unsafe/addictive/needs monitoring” only becomes meaningful once you define monitoring (labs? interaction checks? pregnancy risk? BP follow-up?) and specify the decision pathway for Rx --> OTC switches.

The interesting question isn’t whether the idea is good or bad - it’s what criteria and guardrails you’d actually use. Antibiotics, pseudoephedrine, narrow therapeutic index drugs, pharmacist-gated meds… they all land differently once you get specific.
Seems like two different instincts here. One is the precautionary “more casual access could push resistance” & the other is “if that’s true we should see it where access is looser”.

The tricky part is that resistance doesn’t show up as “people I know got into trouble”, it shows up in surveillance data over years. Some countries that had easy access actually tightened rules after seeing rising resistance, but it’s also not the only factor - prescribing culture and stewardship matter a lot.

Probably the useful question is what do the actual trends look like in places with OTC access?
It depends on what you mean by a superbug - presumably has resistance to all known antibiotics. Thankfully we don't have those, but we have plenty with multi-drug antibiotic resistance. They mean harder to treat infections, longer to get better, more expensive, often only available by IV (so you have to be in hospital where you're at risk of nosocomial infections), more side effects of the big gun antibiotics. We'd be speeding up the clock on antibiotic resistance and it's under-invested in because these meds aren't big money-makers, but that would probably change in a world of OTC antibiotics.
I think this is part of the point. Why legislate to contain costs of insurance, expand access to providers trained in exercising medical judgement and how to safely administer medications when we can just let people assume the risks and the costs themselves. We have a saying in our field that the doctor who treats himself has a fool for a patient - and that's meant to caution people who have medical training about the risks of self-treatment.
My read is that Flats was riffing on the familiar “buried breakthrough” thread storyline rather than endorsing it, sort of pointing out how these claims tend to cluster (secret cancer cures, miracle carburetors, etc).

That said, your breakdown of patents is useful because it shows why these stories don’t map well onto how innovation processes (be they for carburetors or chemo) actually function. It’s a nice example of how sometimes we’re debating narratives as much as facts.
People aren't wrong to intuit that distortions in medical markets exist and they make this intuitive cognitive jump:

If the system has profit distortions --> maybe breakthroughs get hidden.

But how distortions actually show up in the world is really quite complex & variable depending on the kind of distortion. E.g., high prices yields access barriers, patent games result in delays in generics, administrative complexity turns into waste, and there is a robust literature for all of it. But where is that for suppressed cures? You can't find it and have to appeal to CT-logic (conspirators naturally conceal evidence) to preserve the possibility, and that's plausible enough to keep people hanging in for it if they're motivated to believe it (and lots of people get shafted by the medical system in many ways and many other industries as well, so there are lots of such people out there). Unfound suppressed cures could of course just still be hidden just waiting to be found, but meanwhile year after year modern medicine is doing this to cancer survival whether those suppressed cures are there or not: